Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,311,812
-
Share change
-
-317,285
-
Total reported value
-
$3,139,000
-
Price per share
-
$2.40
-
Number of holders
-
23
-
Value change
-
-$766,851
-
Number of buys
-
7
-
Number of sells
-
4
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2016
As of 30 Sep 2016,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,311,812 shares.
The largest 10 holders included
VANGUARD GROUP INC, SABBY MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Fund Advisors, Psagot Investment House Ltd., BlackRock Institutional Trust Company, N.A., NORTHERN TRUST CORP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Bank of New York Mellon Corp, and M&T Bank Corp.
This page lists
23
institutional shareholders reporting positions in this security
for the Q3 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.